Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. Animals bearing BPDCN patient–derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on 2 patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses. We propose that venetoclax or other BCL2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic biomarker. Significance: Therapy for BPDCN is inadequate, and survival in patients with the disease is poor. We used primary tumor cell functional profiling to predict BCL2 antagonist sensitivity as a common feature of BPDCN, and demonstrated in vivo clinical activity of venetoclax in patient-derived xenografts and in 2 patients with relapsed chemotherapy-refractory disease. Cancer Discov; 7(2); 156–64. ©2016 AACR. This article is highlighted in the In This Issue feature, p. 115
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the selective anti-cancer activity of venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has finally validated the clinical utility of directly targeting tumor cell death16–18.”
From Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies (2019) · cites this paper as [18]
In the citing paper
“BIM is essential for BAX/BAK activation and apoptotic engagement18.”
From Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies (2019) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
Montero, J., Sarosiek, K. A., DeAngelo, J. D., Maertens, O., Ryan, J., Ercan, D., Piao, H., Horowitz, N. S., Berkowitz, R. S., Matulonis, U., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.042 · Cited by 378 · cited 2×
“We performed dynamic BH3 profiling (15), which measures the increase in apoptotic priming induced by incubation with a drug.”
MethodSelf-citationThe Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.008 · Cited by 295 · cited 1×
“6 To test this hypothesis in primary cells, we analyzed patient bone marrow aspirates and skin biopsies involved by BPDCN, as well as BPDCN patient-derived xenografts (PDXs) (17).”
BackgroundSelf-citationThe public repository of xenografts enables discovery and randomized phase II-like trials in mice
Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.008 · Cited by 80
Self-citation
Cited by
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Singh, R., Letai, A., & Sarosiek, K. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0089-8 · Cited by 2,111
Self-citationTagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Pemmaraju, N., Lane, A. A., Sweet, K. L., Stein, A. S., Vasu, S., Blum, W., Rizzieri, D. A., Wang, E. S., Duvic, M., Sloan, J. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815105 · Cited by 437
Self-citationDiNardo, C. D., Rausch, C. R., Benton, C., Kadia, T., Jain, N., Pemmaraju, N., Daver, N., Covert, W., Marx, K. R., Mace, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25000 · Cited by 424
Self-citationWhy do BCL-2 inhibitors work and where should we use them in the clinic?
Montero, J., & Letai, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.183 · Cited by 327
Self-citationBH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 287
Metadata
- Authors
- Montero, J., Stephansky, J., Cai, T., Griffin, G. K., Cabal-Hierro, L., Togami, K., Hogdal, L. J., Galinsky, I., Morgan, E. A., Aster, J. C., Davids, M. S., LeBoeuf, N. R., Stone, R. M., Konopleva, M., Pemmaraju, N., Letai, A., & Lane, A. A.
- Venue
- Cancer Discovery
- Published
- 2017-02-01
- Volume
- 7
- Issue
- 2
- Pages
- 156-164
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2564841244
- Cited by
- 212
- References
- 3
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.